Tag: syndrome

Global & Regional Epidemiology

• Global burden (2019): Approximately 150,095 cases globally; age‑standardized prevalence of ~1.9 per 100,000 population BioMed Central.
• Regional differences (2019): Highest age‑standardized prevalence found in:
  • High‑income Asia Pacific (≈ 6.4 per 100,000)
  • High‑income North America (≈ 4.2)
  • Central Latin America (≈ 3.9)
  Lowest rates in East Asia (≈ 0.8), Oceania (≈ 1.0), and Southeast Asia (≈ 1.1) BioMed CentralPMC.
• Trends: Most regions experienced an increase in both prevalence and years lived with disability (YLD) from 1990 to 2019, except for declines in Tropical and Andean Latin America PMC.
• Country-level extremes (2019):
  • Highest prevalence: Japan (~6.4 per 100,000), Brunei, and Singapore PMCPubMed.
  • Lowest prevalence: China (~0.8 per 100,000), North Korea PMCPubMed.

---

Incidence & Risk Factors

• Annual incidence globally: Ranges from 0.6 to 4.0 per 100,000 population PMCWikipedia.
• Systematic review (1980–2008): Incidence estimated at 1.1–1.8 per 100,000 per year, rising to 3.3 per 100,000 in those over 50 years PubMed.
• Children (0–15 years): Incidence between 0.34–1.34 per 100,000 PubMed.
• Common triggers: About 70% of cases are preceded by infections—gastrointestinal or respiratory. Notable pathogens include Campylobacter jejuni, CMV, EBV, Mycoplasma pneumoniae, dengue, and Zika viruses PMCWikipedia.

---

Epidemiology in Tertiary Care Centers – Regional Insights

1. Pakistan (Karachi, 1995–2003)

• Cases: 34 patients (ages 3–70); mean onset age around 30–35 years; male-to-female ratio 1.6:1 PubMed.
• Antecedent events: GI infections (≈ 54.6%) and URTIs (≈ 40.9%) PubMed.
• Complications: Cranial nerve involvement (88%), autonomic dysfunction (62%), respiratory failure requiring ventilation (56%) PubMed.
• Outcomes: Low in-hospital mortality (~2.4%); functional improvements noted after treatment with plasmapheresis or IVIG PubMed.

2. Thailand (2009–2014)

• Study at Thammasat University & Bangkok Hospital: 30 adult patients; 60% male; average age 54 years PubMed.
• Subtypes: AIDP (66.7%), AMAN (10%), other variants (23.3%) PubMed.
• Treatment: IVIG (83.3%), plasma exchange (3.3%) PubMed.
• Ventilation & hospital stay: Assisted ventilation in 13.3%; average length of stay ~14 days PubMed.
• Outcomes: At 1-year follow-up, 63.3% had good recovery (disability score <3); no deaths reported PubMed.

3. Oman (Muscat, 2016–2018)

• Sample size: 44 patients; 63.6% male; average age ≈ 43 years nsj.org.sa.
• Variant distribution: AIDP most common (52%) nsj.org.sa.
• Ventilation: Required in ~13.6% of cases nsj.org.sa.
• Outcomes: Good recovery observed over an 18-month follow-up period nsj.org.sa.
• Context: Incidence aligns with global rate of 1–2 per 100,000 per year; males about 1.5 times more affected nsj.org.saWikipedia.

4. India (Ahmedabad, 2015–2017)

• Study at Sheth V.S. Hospital (tertiary center): 50 patients diagnosed with GBS PMC.
• Incidence: Consistent with global rate (1–2 per 100,000) PMC.
• Subtypes: AIDP and AMAN equally present; AMAN more common in younger patients PMC.
• Triggers & prognosis: Common antecedent events; younger patients generally have better outcomes PMC.

---

Synthesis: Key Themes Across Tertiary Centers

Feature	Observations
Incidence	Generally aligns with global range (0.6–4 per 100,000 annually)
Age & Sex	Affects all age groups; average age often in 30s–50s; male predominance (~1.5:1)
Antecedent Events	Infections (GI, respiratory) common triggers
Subtypes	AIDP predominant; AMAN and others vary by region
Severity & Complications	Respiratory involvement requiring ventilation varies (13–56%); cranial/autonomic involvement common
Treatment	IVIG widely used; plasma exchange utilized less frequently
Outcomes	Low mortality in modern care; majority show functional recovery; favorable long-term outcomes with supportive care

---

Tailored Content Outline for a Publication on GBS Epidemiology in Tertiary Centers

1. Introduction
   • Define GBS and outline its global disease burden and regional variability.
2. Global & Regional Prevalence
   • Present data highlighting geographic differences and temporal trends (1990–2019).
3. Incidence & Demographic Patterns
   • Discuss incidence rates globally and among children.
   • Address age-related increase in risk and male predominance.
4. Triggering Factors
   • Explain the role of antecedent infections (e.g., Campylobacter, EBV, Zika) in GBS onset.
5. GBS in Tertiary Care Settings
   • Draw on case studies from Pakistan, Thailand, Oman, and India:
     • Present demographic profiles, subtype distribution, clinical severity, treatments, and outcomes.
6. Comparative Analysis
   • Highlight similarities and variations across regions:
     • Incidence alignment with global data.
     • Differences in subtype distribution and complication rates.
     • Uniformity in treatment protocols (IVIG) and prognosis outcomes.
7. Implications for Practice
   • Emphasize early recognition, access to immunotherapy, and multidisciplinary supportive care to optimize outcomes.
8. Conclusions
   • Reinforce that while GBS is relatively rare, tertiary centers must be equipped and vigilant.
   • Encourage region-specific epidemiological tracking to tailor healthcare strategies.